

# Michael J Spinella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8689117/publications.pdf>

Version: 2024-02-01

46  
papers

2,131  
citations

236925

25  
h-index

233421

45  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2355  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy. <i>Molecular Oncology</i> , 2022, 16, 683-698.	4.6	10
2	Toward a Mechanistic Understanding of Poly- and Perfluoroalkylated Substances and Cancer. <i>Cancers</i> , 2022, 14, 2919.	3.7	25
3	Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours. <i>Epigenetics</i> , 2021, 16, 1071-1084.	2.7	21
4	A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer. <i>Cancer Medicine</i> , 2021, 10, 156-163.	2.8	23
5	Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors. <i>Cancers</i> , 2021, 13, 1506.	3.7	18
6	The potential of retinoids for combination therapy of lung cancer: Updates and future directions. <i>Pharmacological Research</i> , 2019, 147, 104331.	7.1	16
7	Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors. <i>Cancers</i> , 2019, 11, 796.	3.7	25
8	Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors. , 2019, 2, 580-594.		35
9	Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review. <i>Targeted Oncology</i> , 2018, 13, 49-60.	3.6	5
10	GOS2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. <i>Cell Cycle</i> , 2017, 16, 2146-2155.	2.6	15
11	Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. <i>Oncotarget</i> , 2017, 8, 2949-2959.	1.8	57
12	GOS2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program. <i>Cancer Research</i> , 2016, 76, 1204-1213.	0.9	42
13	All- <i>trans</i> -retinoic acid antagonizes the hedgehog pathway by inducing patched. <i>Cancer Biology and Therapy</i> , 2014, 15, 463-472.	3.4	9
14	Headway and Hurdles in the Clinical Development of Dietary Phytochemicals for Cancer Therapy and Prevention: Lessons Learned from Vitamin A Derivatives. <i>AAPS Journal</i> , 2014, 16, 281-288.	4.4	3
15	Serine/Threonine Kinase 17A Is a Novel Candidate for Therapeutic Targeting in Glioblastoma. <i>PLoS ONE</i> , 2013, 8, e81803.	2.5	24
16	Acute Hypersensitivity of Pluripotent Testicular Cancer-Derived Embryonal Carcinoma to Low-Dose 5-Aza Deoxycytidine Is Associated with Global DNA Damage-Associated p53 Activation, Anti-Pluripotency and DNA Demethylation. <i>PLoS ONE</i> , 2012, 7, e53003.	2.5	49
17	Serine/Threonine Kinase 17A Is a Novel p53 Target Gene and Modulator of Cisplatin Toxicity and Reactive Oxygen Species in Testicular Cancer Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 19381-19391.	3.4	39
18	Modulation of Clock Gene Expression by the Transcriptional Coregulator Receptor Interacting Protein 140 (RIP140). <i>Journal of Biological Rhythms</i> , 2011, 26, 187-199.	2.6	18

#	ARTICLE	IF	CITATIONS
19	Retinoic Acid Mediates Long-Paced Oscillations in Retinoid Receptor Activity: Evidence for a Potential Role for RIP140. PLoS ONE, 2009, 4, e7639.	2.5	8
20	High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors. Cancer Research, 2009, 69, 9360-9366.	0.9	91
21	Nestin Is Expressed in the Basal/Myoepithelial Layer of the Mammary Gland and Is a Selective Marker of Basal Epithelial Breast Tumors. Cancer Research, 2007, 67, 501-510.	0.9	116
22	Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells. Current Cancer Therapy Reviews, 2006, 2, 255-270.	0.3	23
23	p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53. Oncogene, 2005, 24, 1481-1490.	5.9	14
24	A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene, 2005, 24, 6090-6100.	5.9	85
25	Limiting Effects of RIP140 in Estrogen Signaling. Journal of Biological Chemistry, 2005, 280, 7829-7835.	3.4	29
26	Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene, 2003, 22, 7305-7315.	5.9	297
27	Negative Feedback at the Level of Nuclear Receptor Coregulation. Journal of Biological Chemistry, 2003, 278, 43889-43892.	3.4	33
28	Retinoid Target Gene Activation during Induced Tumor Cell Differentiation: Human Embryonal Carcinoma as a Model. Journal of Nutrition, 2003, 133, 273S-276S.	2.9	28
29	Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2. Gene, 2002, 291, 17-27.	2.2	26
30	Developmentally-related candidate retinoic acid target genes regulated early during neuronal differentiation of human embryonal carcinoma. Oncogene, 2002, 21, 2880-2889.	5.9	87
31	Transcriptional Activation of the Nuclear Receptor Corepressor RIP140 by Retinoic Acid: A Potential Negative-Feedback Regulatory Mechanism. Biochemical and Biophysical Research Communications, 2001, 285, 969-975.	2.1	62
32	Cyclin Proteolysis as a Retinoid Cancer Prevention Mechanism. Annals of the New York Academy of Sciences, 2001, 952, 13-22.	3.8	38
33	Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function. Oncogene, 2001, 20, 2559-2569.	5.9	51
34	Aberrant Retinoid Signaling and Breast Cancer: the View From Outside the Nucleus. Journal of the National Cancer Institute, 2000, 92, 438-440.	6.3	11
35	Retinoic Acid Promotes Ubiquitination and Proteolysis of Cyclin D1 during Induced Tumor Cell Differentiation. Journal of Biological Chemistry, 1999, 274, 22013-22018.	3.4	139
36	4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RAR $\alpha$ independent pathway. Oncogene, 1999, 18, 5747-5755.	5.9	44

#	ARTICLE	IF	CITATIONS
37	Genesis, a Winged Helix transcriptional repressor, has embryonic expression limited to the neural crest, and stimulates proliferation in vitro in a neural development model. <i>Cell and Tissue Research</i> , 1999, 297, 371-382.	2.9	53
38	Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. <i>Oncogene</i> , 1998, 16, 3471-3480.	5.9	34
39	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. <i>Oncogene</i> , 1998, 17, 761-767.	5.9	31
40	pH Dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. <i>Biochemical Pharmacology</i> , 1997, 53, 223-231.	4.4	64
41	Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. <i>Biochemical Pharmacology</i> , 1996, 52, 703-712.	4.4	17
42	Distinguishing between Folate Receptor-mediated Transport and Reduced Folate Carrier-mediated Transport in L1210 Leukemia Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 7842-7849.	3.4	106
43	Characterization of a Mutation in the Reduced Folate Carrier in a Transport Defective L1210 Murine Leukemia Cell Line. <i>Journal of Biological Chemistry</i> , 1995, 270, 22974-22979.	3.4	104
44	Comparison of transport properties of the reduced folate carrier and folate receptor in murine L1210 leukemia cells. <i>Biochemical Pharmacology</i> , 1995, 50, 1287-1294.	4.4	33
45	Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. <i>Biochemical Pharmacology</i> , 1994, 47, 337-345.	4.4	67
46	Endothelin-receptor interactions. <i>FEBS Letters</i> , 1993, 328, 82-88.	2.8	6